Latest Period
Q1 2026
Security Snapshot
Radiopharm Theranostics Ltd - Ordinary Shares, no par value and American Depositary Shares, each representing three hundred Ordinary Shares, no par value (RADX) Institutional Ownership
CUSIP: 75041J101
13F Institutional Holders and Ownership History from Q4 2024 to Q1 2026
Institutions Reporting
7
Shares (Excl. Options)
51,308,037
Price
$4.30
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary Shares, no par value and American Depositary Shares, each representing three hundred Ordinary Shares, no par value
- Symbol
- RADX on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 51,308,037
- Total 13F value
- $2,064,148
- Portfolio coverage rank
- 0%
- Share change
- -231,540
- Value change
- -$1,032,966
- Number of holders
- 7
- Shares outstanding
- 3,543,587,624
- SEC-reported price per share
- $4.52
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- RADX - Radiopharm Theranostics Ltd - Ordinary Shares, no par value and American Depositary Shares, each representing three hundred Ordinary Shares, no par value is tracked under CUSIP 75041J101.
- 7 institutions reported positions in Q1 2026.
- 1 significant owner is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 10 to 7 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $2,823,133 to $2,064,148.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 7 institutions filings for Q1 2026.
Security key
75041J101
Latest holder period
Q1 2026
13F holders
7
13D/G owners
1
CIK / CUSIP context first
Open Q1 2026 holders
RADX full holder history
Radiopharm Theranostics Ltd SEC filings
Radiopharm Theranostics Ltd company facts
Radiopharm Theranostics Ltd insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 75041J101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
1
Security
RADX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| REGAL PARTNERS HOLDINGS PTY LTD | 9% | +25% | $1,362,952,390 | +$629,253,691 | 320,694,680 | +86% | Regal Partners Holdings Pty Limited | 31 Dec 2025 |
As of 31 Mar 2026, 7 institutional investors reported holding 51,308,037 shares of Radiopharm Theranostics Ltd - Ordinary Shares, no par value and American Depositary Shares, each representing three hundred Ordinary Shares, no par value (RADX). This represents 1.4% of the company’s total 3,543,587,624 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
6
Latest
Q1 2026
Rows shown
1-6 of 6
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 51,308,037 | $2,064,148 | -$1,032,966 | $4.30 | 7 |
| 2025 Q4 | 539,577 | $2,823,133 | +$1,191,852 | $5.22 | 10 |
| 2025 Q3 | 312,506 | $1,725,033 | -$119,409 | $5.52 | 4 |
| 2025 Q2 | 339,690 | $1,576,875 | -$15,543 | $4.64 | 5 |
| 2025 Q1 | 342,915 | $1,649,421 | -$446,370 | $4.81 | 3 |
| 2024 Q4 | 435,803 | $1,939,576 | +$1,939,576 | $4.49 | 4 |